{'52WeekChange': 1.2427654,
 'SandP52WeekChange': None,
 'address1': '4464 Markham Street',
 'address2': 'Suite 1203',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.85,
 'askSize': 1000,
 'averageDailyVolume10Day': 3995287,
 'averageVolume': 1489025,
 'averageVolume10days': 3995287,
 'beta': 1.122552,
 'beta3Year': None,
 'bid': 13.71,
 'bidSize': 800,
 'bookValue': 2.342,
 'category': None,
 'circulatingSupply': None,
 'city': 'Victoria',
 'companyOfficers': [],
 'country': 'Canada',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.4236,
 'dayLow': 13.63,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -15.094,
 'enterpriseToRevenue': 4045.455,
 'enterpriseValue': 1286454784,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '250-744-2498',
 'fiftyDayAverage': 15.398571,
 'fiftyTwoWeekHigh': 21.93,
 'fiftyTwoWeekLow': 3.52,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 82301399,
 'forwardEps': -0.55,
 'forwardPE': -25.30909,
 'fromCurrency': None,
 'fullTimeEmployees': 62,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.17108,
 'heldPercentInstitutions': 0.49677,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1382486400,
 'lastSplitFactor': '1:50',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/auriniapharma.com',
 'longBusinessSummary': 'Aurinia Pharmaceuticals Inc., a clinical stage '
                        'biopharmaceutical company, develops and '
                        'commercializes therapies to treat various diseases in '
                        'the United States and China. It is involved in '
                        'developing voclosporin, an investigational drug for '
                        'the treatment of lupus nephritis, dry eye syndrome, '
                        'and focal segmental glomerulosclerosis. The company '
                        'is headquartered in Victoria, Canada.',
 'longName': 'Aurinia Pharmaceuticals Inc.',
 'market': 'us_market',
 'marketCap': 1563536128,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_882669',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -127952000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.03,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '250-744-2487',
 'previousClose': 13.95,
 'priceHint': 2,
 'priceToBook': 5.943638,
 'priceToSalesTrailing12Months': 4916.7803,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.4236,
 'regularMarketDayLow': 13.63,
 'regularMarketOpen': 14.03,
 'regularMarketPreviousClose': 13.95,
 'regularMarketPrice': 14.03,
 'regularMarketVolume': 3693678,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 112634000,
 'sharesPercentSharesOut': 0.0429,
 'sharesShort': 4834808,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4200324,
 'shortName': 'Aurinia Pharmaceuticals Inc',
 'shortPercentOfFloat': None,
 'shortRatio': 3.58,
 'startDate': None,
 'state': 'BC',
 'strikePrice': None,
 'symbol': 'AUPH',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.298,
 'twoHundredDayAverage': 16.50777,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '6af70c53-6225-3411-b004-ce20a00fb8bf',
 'volume': 3693678,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.auriniapharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'V8Z 7X8'}